Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent email.
That's at least a positive...let's hope he gets the message and he/ counsel/ accounting firm get things done. Just as importantly, he needs to be much more communicative with Watkins and at least keep him in the loop with what is going on.
Today was a huge setback, but I'm not ready to give on UNSS, just yet!
I did. He's responded sometimes in the past with very limited info, but rarely.
From Watkins:
"I really want it, UNSS, to work out.
But three years was way to long... and our discussions on Wall Street had some negative "explaining".
So... Let's hope..."
Paul can turn this ship around still, but he's got to do it soon.
Ok, that's a glimmer of hope and if that doesn't light a fire under Landrews 4ss then nothing will!
Same, lost a lot of money. I'm following Watkins wherever he takes Entrex, ideally UNSS if Paul can turn things around but its looking grim unless he can spin on a dime. Seems to me like they are so close but maybe I'm wrong.
I don't think he can be removed since we control the float, but not the outstanding (including restricted) shares. He's got to through plain and simple, and do his job!
That's our only hope obviously but it has to be soon, before Entrex finds another shell to merge into.
Very disappointing. Paul really let us down.
I envy whoever bought those cheapies! This is still a low volume sell. The Ask is still very thin so it only takes one or two buyers to get it back up.
I think they are learning to not overpromise on timelines Lol
Good post. I was going to point out before anyone panics about UNSS that most companies don’t have their annual financial reports out, yet. Due March 31, 2022 as you point out.
UNSS LONG AND STRONG
Looks worst than it is. Very small volume Sell. Probably the same person that sold some last week. Still very little resistance going back up.
Oh I just got your post. Didn't know the market was closed today Lol
The worse. I like to invest in stocks I don't believe in and make non sensical comments for months in the chatroom Lol
I'm concerned for their mental health. The definition of insanity, really.
I don’t think he lets facts get in the way of his lies Lol
I get it. It's good to counter people who lie.
Are you seeing insignificant ghost posts Lol. I blocked those liars a long time ago. They are waste of space in my books and not worth our energy. :)
UNSS LONG & STRONG
Here's an interesting article on Carbon credits.
https://ca.finance.yahoo.com/news/carbon-credits-outperforming-bitcoin-bet-longer-energy-transition-144103550.html
This is what really stood out for me:
"The global emissions trading market could be worth as much as $22 trillion by 2050, according to an estimate last year from Wood Mackenzie"!!
UNSS-Entrex is in a great position to capitalize on this astronomical market.
UNSS LONG & STRONG
Sorry, you are negative about positive PRs so I can't really waste my time here. I am Long. Time will tell if TBPMF is successful.
I used it a long time ago on people who mislead or lie. For example, I see someone replied to me today but I don't see their dumb ignorant post. They are an insignificant ghost. It's such a nice feature Lol
They were probably in need of quick cash. Why else would anyone sell at this stage when fins are just around the corner. Those shares are going to be worth a lot more soon and Float is even more locked!
UNSS LONG AND STRONG
If he thinks it’s getting delisted and hasn’t sold his shares than he is clearly spreading misinformation. Either way, he’s unsuccessfully trying to manipulate. Tells you what kind of person he is.
More great news! Tetra Bio-Pharma gets approval for C$4.5M loan from Québec authority
Feb. 16, 2022 8:37 AM ETTetra Bio-Pharma Inc. (TBPMF)By: Ravikash, SA News Editor
Tetra Bio-Pharma (OTCQB:TBPMF) announced the approval of a C$4.5M participative loan from the ministère de l'Économie et de l'Innovation under the BioMed Propulsion Program, managed by Investissement Québec.
The company said the funding will support the development of ARDS-003 for acute respiratory distress syndrome whether or not it is caused by COVID-19; as well as in patients with Sepsis.
This company noted that the transaction is conditional on the approval of all shareholders and will be subject to a vote at the General Meeting in May 2022 since it will require the transfer of its head office from Ontario to the province of Quebec and the approval of certain financial terms.
Exactly. Annual Fins deadline is only March 31st. It's unfortunate our expectations were Feb 1, 2022 based on what Watkins was told. Obviously this was a miscalculation. Had we not been given that estimate, we would not be disappointed and would be eagerly anticipating Fins and Letter submission before the deadline.
Congrats to whoever picked up the cheapies. That means float is even more locked. I am so pumped for the coming weeks and months!!!
UNSS LONG AND STRONG
Annual reports take longer is one reason. Documents need collecting. It's why I can't do my taxes right now, Lol.
I'm pretty sure it's in the hands of the third party accounting, not Paul at this point. Paul had mentioned in the past that they see UNSS as a small fish in the the sea, so they are not as high on the priority list (for now) so we are at their mercy. I'm afraid sitting tight is all we can do.
UNSS LONG & STRONG
No worries here. Watkins is very much on board with Paul and UNSS.
Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna
02/14/2022
The proposed partnership will encompass three potential strategic pillars across supply of API, commercialization of prescription products, and co-development of pharmaceutical drug candidates.
OTTAWA, ON, Feb. 14, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced today that it has executed a non-binding term sheet with Avicanna Inc. ("Avicanna") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) to assess entering into a strategic partnership comprising of three strategic pillars, including:
Tetra Bio-Pharma Logo (CNW Group/Tetra Bio-Pharma Inc.)
The registration and commercialization of Tetra's various prescription products (REDUVO™ AdVersa®, QIXLEEF™ and CAUMZ™) across Avicanna's channels in Latin/South America. This opens the door for Tetra to initiate sales earlier than planned.
Supply of Avicanna's Active Pharmaceutical Ingredients (APIs) for Tetra's pharmaceutical pipeline. The phyto-cannabinoid APIs would be sourced from Avicanna's low cost and sustainable operations in Colombia.
Co-development and support for Avicanna's pharmaceutical pipeline for Health Canada and FDA level clinical development and registration.
Steeve Neron, Chief Commercial Officer at Tetra stated, "Tetra will need multiple reliable suppliers of API, like Avicanna, to support QIXLEEF™ operations leading to its successful marketing authorization and global sales and distribution. QIXLEEF™ is Tetra's proprietary investigational new drug and is currently being evaluation in two U.S. FDA-authorized clinical trials. Additionally, Avicanna's established distribution channels in Latin/South America may help advance Tetra's product commercialization in select jurisdictions".
Aras Azadian, Chief Executive Officer of Avicanna also commented on the opportunity. "We look forward to collaborating with the Tetra team who has in many ways been pioneering cannabinoid- prescription products. As the global industry continues to mature and shift its focus towards evidence-based medicines, the two companies are well positioned to work in synergy across several projects and leverage their leadership positions into fruitful commercial results."
About Avicanna Inc.
Avicanna is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The Company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development that has led to the commercialization of more than twenty products across four main market segments: Cannabis Raw Materials (API) and feminized Seeds (marketed under the Aureus™ brand), Pharmaceutical Pipeline, Medical Cannabis & Wellness Products and CBD Derma Cosmetic Products.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Great news! They will be able to go to market much sooner in Latin America thanks to this partnership.
https://twitter.com/arsenam11/status/1493199058592321536?s=21
This is an even better set up - Float 100% locked. Thanks for the update.
Fins are due March 31st, so I believe they will be early, despite being later then we all want them. Q4 is an Annual Report so they do take a bit longer. Come on Paul, get'er done!!!
UNSS LONG AND STRONG
He’s ‘only’ got 60 million shares. More than the entire float Lol
Looks like someone is loading up. News coming?
The biggest issue which really delayed things early on was that Calloway was being kicked out as president. He probably didn't want to sign the fins until he was given shares in exchange for him stepping down. He has a criminal charge in litigation against him (unrelated to UNSS)...make your own conclusions.
My understanding was there were other issues brought up by the OTC that needed to be addressed in the Q3 Fins. As far as I know, all has been addressed. Watkins had mentioned other internal matters need to be addressed which were resolved earlier this year.
All this brings us to now. As far as Watkins is aware, there are no more issues and Q4 should come out on time, and hopefully earlier.
Exactly. The wait has been excruciating for all of us but there has to be a reason Fins keep getting submitted, otherwise it would be a huge waste of money for UNSS. Q4 and letter might be a few weeks later than what we hoped for, but what’s a few weeks when we’ve been this patient for these 2 years. For my part, this has always been a 3 to 5 year hold based on Entrex’s long term plan. I’m convinced more than ever we will get there. Time will tell.
UNSS LONG AND STRONG
Watkins was quite clear, he is believes Paul will get it done, again not If but When. He is not going anywhere and is concentrating on the business to bring what will be tremendous shareholder value.
It’s not that long for a huge payout!
The difference is there were some obstacles/ issues which have now been addressed. As long as OTC agrees with this assessment, we now have a clean shell ticker and CE will be removed in the next 2-10 weeks.
Watkins update: he's is concentrating on the business side as he should since the opportunities in the carbon credit market are insane, and letting Paul deal with reporting. Like everyone, he's frustrated with how much time it's taking but still firmly believes it's not If but When.
I'm not confident Paul will deliver by end of week based on his track record, but it will happen and I remain patient. The reward is so worth it. AIMHO.
UNSS Long & Strong